Provider/Grant Support
This program has been funded by an unrestricted educational grant from Calliditas.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed for a US-based audience of academic and community nephrologists and other healthcare practitioners involved in the management of IgAN.
Program Overview
Join leading nephrology experts for a series of 15-minute talking head videos that delve into the significant clinical burden of IgA nephropathy (IgAN), the underlying immune mechanisms driving disease progression, and the latest therapeutic advances transforming its management. The series emphasizes the importance of timely identification and diagnosis to ensure patients are connected to appropriate care and highlights how emerging therapies, targeting various stages of the IgAN pathogenic pathway, are reshaping the treatment landscape.
Episode 4: Making progress: B cell-directed therapies in IgAN
Jonathan Barratt & Richard Lafayette
Duration: 15:54 minutes
- Role of the gut mucosal immune system and mucosal-derived Gd-IgA1 in the pathogenesis of IgAN (reference to immune mechanism session)
- Mechanism of action of Nefecon® (modified-release budesonide)
- Overview of efficacy and safety data of Nefecon in IgAN from the phase 2 and phase 3 studies that led to approval in patients with IgAN at high risk of progression to kidney failure
- Guideline recommendations for Nefecon in IgAN
- Overview of other products in development that act on B cells (e.g., monoclonal antibodies to CD38, a proliferation-inducing ligand [APRIL] or B cell-activating factor [BAFF]) with overview of ongoing studies
Episode 5: Making progress: Complement inhibitors in IgAN
Jonathan Barratt & Gaia Coppock
Duration: 20:28 minutes
- Overview of how tissue deposition of Gd-IgA1 can trigger local complement activation
- Mechanism of action of therapies targeting complement pathways that are being investigated in IgAN
- Key clinical data from trials investigating complement inhibitors in patients with IgAN
- Guideline recommendations for complement inhibitors in IgAN
Episode 6: Making progress: Supportive care in IgAN
Jonathan Barratt & Sayna Norouzi
Duration: 18:40 minutes
- Managing the consequences of IgAN-induced nephron loss
- Rationale for targeting the endothelin pathway as well as the renin-angiotensin-aldosterone-system in IgAN with endothelin angiotensin receptor antagonists (ERA) and dual ERA (DEARA)
- Clinical trial data investigating the efficacy and safety of ERA and DEARA in IgAN
- Guideline recommendations for ERA and DEARA in IgAN
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the signs and symptoms of IgAN and those patients who are at risk of disease progression
- Evaluate how proteinuria and estimated glomerular filtration rate assessments can be used to identify patients at risk of IgAN and when referral for biopsy is required in order to confirm the diagnosis
- Describe the immune processes underlying development and progression of IgAN
- Discuss targets for disease-modifying therapy based on the mechanisms underlying IgAN
Gauge
GAUGE is Nexus Healthcare Education’s (Nexus HE’s) advanced outcome measurement tool, uniquely designed to evaluate the real-world impact of learning on clinical practice and patient care. In completing each of GAUGE's outcome assessments, you actively contribute to advancing the quality of healthcare education.
How GAUGE works
- Participation tracking: GAUGE monitors your engagement, including time spent on modules, and completion rates, providing insights into commitment to learning.
- Satisfaction feedback: After listening to the episodes, you will be asked to complete a satisfaction survey. This helps us capture your perceptions, identify strengths, and pinpoint areas for improvement to continually optimize our programs.
- Knowledge assessment: Pre- and post-module quizzes are used to measure knowledge gains. These assessments are designed to ensure the program effectively addresses your practice needs and supports your growth in clinical competence.
- Competency evaluation: Using practical, case-based scenarios via the Clinical Challenge Quiz, GAUGE evaluates readiness to apply new knowledge in real-world settings. Follow-up assessments at 1, 3, and 6 months post completion help track confidence and ability to implement changes over time.
- Performance and patient care impact: Through self-reported Patient Care Logs, GAUGE tracks the direct consequences of learning on clinical behavior and patient outcomes. Logging applications of new skills provides valuable data on patient care improvements. You are encouraged to update the log frequently, with reminders sent at 1 and 5 months after module completion.
Faculty
Jonathan Barratt, MD
Professor of Renal Medicine
University of Leicester, UK
Richard Lafayette, MD, FACP
Professor of Medicine (Nephrology)
Stanford University School of Medicine, CA USA
Gaia Coppock, MD
Assistant Professor of Clinical Medicine (Renal-Electrolyte and Hypertension)
University of Pennsylvania, PA USA
Sayna Norouzi, MD, FASN
Assistant Professor of Medicine, Clinical Nephrologist
Loma Linda University Medical Center, CA USA
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners and Nexus HE. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nurses Credentialing Center to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™ per episode. Physicians should claim only the credit commensurate with the extent of their participation.
Disclosure of Conflict of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners’ policies. Others involved in the planning of this activity have no relevant financial relationships.
Jonathan Barratt
Received consultancy fees for providing speaker service to Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Argenx SE, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas, Chinook Therapeutics, Dimerix, Galapagos NV, Novartis, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, and Visterra.
Received research grants from Argenx SE, Calliditas, Chinook Therapeutics, Galapagos NV, GlaxoSmithKline (GSK plc), Novartis, Omeros Corporation, Travere Therapeutics, and Visterra.
Richard Lafayette
Received consultancy fees for providing speaker services to Alexion Pharmaceuticals, Biogen, Novartis, Takeda, Vera Therapeutics, and Vertex.
Gaia Coppock
Received consultancy, speaker and/or advisory fees from Apellis Pharmaceuticals, Calliditas Therapeutics, Travere Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical, and Novartis.
Sayna Norouzi
Received consultancy fees from Alexion Pharmaceuticals, Otsuka Pharmaceutical, Calliditas, Novartis, and Travere Therapeutics.
Received speaker fees from Otsuka Pharmaceutical, Calliditas, and Eli Lilly and Company.
Computer System Hardware/Software Requirements
To access and participate in this activity hosted on the Nexus HE Learning HUB, users will need a desktop or laptop computer running Windows (version 10 or later) or macOS (version 10.14 or later). Alternatively, mobile devices such as iOS devices (iOS 14 or later) or Android devices (Android 8.0 or later) can be used. A stable broadband internet connection with a minimum download speed of 5 Mbps is required for streaming audio content. Participants should use a web browser such as Google Chrome (latest version, recommended), Microsoft Edge (latest version), Safari (latest version), or Mozilla Firefox (latest version) to access the platform. For audio playback, built-in or external speakers or headphones are necessary.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indication(s). The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and further their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions please contact: learning@nexushehub.com.